108 related articles for article (PubMed ID: 151764)
1. Immunological methods employed in an attempt to induce erythema nodosum leprosum (ENL) in mice.
Anthony J; Vaidya MC; Dasgupta A
Lepr India; 1978 Jul; 50(3):356-62. PubMed ID: 151764
[TBL] [Abstract][Full Text] [Related]
2. Changes in circulating antibody levels to the major phenolic glycolipid during erythema nodosum leprosum in leprosy patients.
Andreoli A; Brett SJ; Draper P; Payne SN; Rook GA
Int J Lepr Other Mycobact Dis; 1985 Jun; 53(2):211-7. PubMed ID: 3894538
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cell-mediated immune responses in erythema nodosum leprosum reactions of leprosy.
Rao TD; Rao PR
Int J Lepr Other Mycobact Dis; 1987 Mar; 55(1):36-41. PubMed ID: 3549939
[TBL] [Abstract][Full Text] [Related]
4. IgM antibodies against phenolic glycolipid I from Mycobacterium leprae in leprosy sera: relationship to bacterial index and erythema nodosum leprosum.
Schwerer B; Meeker HC; Sersen G; Levis WR
Acta Leprol; 1984; 2(2-4):394-402. PubMed ID: 6398598
[TBL] [Abstract][Full Text] [Related]
5. Research in leprosy. A report of a committee set up by the medical research council to study future prospects.
Clin Exp Immunol; 1979 Apr; 36(1):1-7. PubMed ID: 380853
[TBL] [Abstract][Full Text] [Related]
6. Activation of complement by Mycobacterium leprae requires disruption of the bacilli.
Lahiri R; Sandoval FG; Krahenbuhl JL; Shannon EJ
Lepr Rev; 2008 Sep; 79(3):311-4. PubMed ID: 19009980
[TBL] [Abstract][Full Text] [Related]
7. Selective decrease of M. leprae-specific IgG1 and IgG3 antibodies in leprosy patients associated with ENL.
Kifayet A; Hussain R
Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):105-14. PubMed ID: 8690967
[TBL] [Abstract][Full Text] [Related]
8. A follow up of T-cell subsets and of anti-M. leprae antibody titer as measured by the FLA-ABS test in Melanesian leprosy patients under polychemotherapy.
Garraud O; Ribierre O; Bach MA
Int J Lepr Other Mycobact Dis; 1986 Mar; 54(1):38-45. PubMed ID: 2940306
[TBL] [Abstract][Full Text] [Related]
9. Suppressive effect of circulating immune complexes from leprosy patients on the lymphocyte proliferation induced by M. leprae antigens in healthy responders.
Tyagi P; Patil SA; Girdhar BK; Katoch K; Sengupta U
Int J Lepr Other Mycobact Dis; 1992 Dec; 60(4):562-9. PubMed ID: 1299711
[TBL] [Abstract][Full Text] [Related]
10. Significance of antibody studies in leprosy and experimental models of the disease.
Harboe M
Int J Lepr Other Mycobact Dis; 1982 Sep; 50(3):342-50. PubMed ID: 6754640
[No Abstract] [Full Text] [Related]
11. Immunological status of ENL (erythema nodosum leprosum) patients: its relationship to bacterial load and levels of circulating IL-2R.
Vieira LM; Sampaio EP; Nery JA; Duppre NC; Albuquerque EC; Scheinberg MA; Sarno EN
Rev Inst Med Trop Sao Paulo; 1996; 38(2):103-11. PubMed ID: 9071029
[TBL] [Abstract][Full Text] [Related]
12. Differential immunoglobulin and complement levels in leprosy prior to development of reversal reaction and erythema nodosum leprosum.
Amorim FM; Nobre ML; Nascimento LS; Miranda AM; Monteiro GRG; Freire-Neto FP; Queiroz MDCP; Queiroz JW; Duthie MS; Costa MR; Reed SG; Johnson WD; Dupnik KM; Jeronimo SMB
PLoS Negl Trop Dis; 2019 Jan; 13(1):e0007089. PubMed ID: 30689631
[TBL] [Abstract][Full Text] [Related]
13. A vaccine from ICRC bacilli against M. leprae infection in mouse foot-pad.
Bhide MB; Pradhan KS; Bapat CV
Lepr India; 1978 Jul; 50(3):334-44. PubMed ID: 359922
[No Abstract] [Full Text] [Related]
14. Treatment of chronic erythema nodosum leprosum with cyclosporine A produces clinical and immunohistologic remission.
Miller RA; Shen JY; Rea TH; Harnisch JP
Int J Lepr Other Mycobact Dis; 1987 Sep; 55(3):441-9. PubMed ID: 3309088
[TBL] [Abstract][Full Text] [Related]
15. Electron microscope study of Erythema nodosum leprosum.
Okada S; Nakai E; Narita M; Takahashi S; Harada N
Int J Lepr Other Mycobact Dis; 1974; 42(1):33-7. PubMed ID: 4137644
[No Abstract] [Full Text] [Related]
16. Thalidomide does not modify the ability of cells in leprosy patients to incorporate [3H]-thymidine when incubated with M. leprae antigens.
Tadesse A; Taye E; Sandoval F; Shannon EJ
Lepr Rev; 2003 Sep; 74(3):206-14. PubMed ID: 14577465
[TBL] [Abstract][Full Text] [Related]
17. In situ and in vitro characterization of the cellular immune response in erythema nodosum leprosum.
Modlin RL; Mehra V; Jordan R; Bloom BR; Rea TH
J Immunol; 1986 Feb; 136(3):883-6. PubMed ID: 2416837
[TBL] [Abstract][Full Text] [Related]
18. In situ identification of activated Ta1+ T lymphocytes in human leprosy skin lesions.
Shen JY; Hofman FM; Gunter JR; Modlin RL; Rea TH
Int J Lepr Other Mycobact Dis; 1987 Sep; 55(3):494-8. PubMed ID: 2443587
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of T-cell unresponsiveness in leprosy.
Bach MA; Hoffenbach A; Lagrange PH; Wallach D; Cottenot F
Ann Immunol (Paris); 1983; 134D(1):75-84. PubMed ID: 6226239
[TBL] [Abstract][Full Text] [Related]
20. Increased activated memory B-cells in the peripheral blood of patients with erythema nodosum leprosum reactions.
Negera E; Walker SL; Bekele Y; Dockrell HM; Lockwood DN
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006121. PubMed ID: 29253897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
